All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Multiple Myeloma Hub

Brought to you by Scientific Education Support

Scientific Education Support

The Multiple Myeloma Hub is an independent medical education platform, sponsored by AbbVie, Roche, Bristol Myers Squibb, Pfizer, GSK, Johnson & Johnson, Legend Biotech and Caribou Biosciences. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

My Multiple Myeloma Hub

Create an account to access:

Bookmark & personalize site content

Receive alerts for new content in your areas of interest

View multiple myeloma content recommended for you

#ASCO22

Share:

Jun 12, 2022

X post image

16 Nov 2022

Midweek catch up!
#ASCO22 | 🎥 the Multiple Myeloma Hub was pleased to speak to Doris Hansen, Moffitt Cancer Center. We asked, Is experience with ide-cel CAR-T in the real-world setting comparable to the KarMMa trial results?
Watch the video here 👇
https://t.co/8KpQeAcxRY

X post image

9 Aug 2022

Does OriCAR-017, a GPRC5D CAR T-cell, have potential to be the future sequencing therapy in patients with R/R MM❓ Find out more 👇 #mmsm #EHA2022 #ASCO22
https://t.co/ygAHdjJ0pH

X post image

3 Aug 2022

👀One of the largest trials in newly diagnosed #myeloma reports its results after more than 6 years of follow-up. Read a summary of the phase III DETERMINATION trial presented at #ASCO22 and #EHA2022 here 👇 #mmsm #bmtsm
https://t.co/C7VRXGPww0

X post image

29 Jul 2022

🎧 During #ASCO22, the Multiple Myeloma Hub was pleased to speak to @RobertoMinaMD, University of Turin, and Andrzej J. Jakubowiak, The University of Chicago. We asked, What are the pros and cons of bispecific antibodies for multiple myeloma❓
https://t.co/Rik9wzvUL6

X post image

7 Jul 2022

🎥 During #ASCO22 , the Multiple Myeloma Hub was pleased to speak to Doris Hansen, Moffitt Cancer Center. We asked, Is experience with ide-cel CAR-T in the real-world setting comparable to the KarMMa trial results❓
Watch the video here 👇
https://t.co/8KpQeAu8Jw

X post image

24 Jun 2022

New data were released at #ASCO22 from the phase I study of CART-ddBCMA in pts with R/R MM. An ORR of 100% was reported, with 94% of pts achieving VGPR or better. There was only 1 case of Grade ≥3 CRS. Read our full article here 👇
#Myeloma #MMsm #Mednews
https://t.co/687GWnkS6o

X post image

16 Jun 2022

An update from #ASCO22 and #EHA2022 of the CARTITUDE-2 trial reports a 100% ORR with cilta-cel in patients with multiple #myeloma relapsing early after 1 prior line of therapy. Read the latest here 👇👀 #mmsm #CARTcell

👉 https://t.co/p93unNL30K 👈

X post image

12 Jun 2022

Teclistamab and talquetamab combined with daratumumab for relapsed #myeloma #ASCO22 #EHA2022 #mmsm https://t.co/EWdr8BHqmB

X post image

8 Jun 2022

Check out our Twitter Moment from #ASCO22⭐️
https://t.co/r2yLuDDXZJ

X post image

7 Jun 2022

We hope you enjoyed following our live updates and congress coverage! 🎓

#ASCO22 was covered by us in Chicago, IL, as well as virtually!

Keep an eye on our socials for post-congress key points and insights! 📲

#medicalcongress #cancerawareness

X post image

6 Jun 2022

CONGRESS #ASCO22 | Samer Ali Srour @MDAndersonNews presents a phase II study of umbilical cord blood–derived NK cells with elotuzumab, lenalidomide, and high-dose melphalan followed by ASCT in patients with high-risk #MM.
N=30.
2-year PFS and OS rates were 83% and 97%.
#mmsm

X post image

6 Jun 2022

RT @HadidiSamer: #mmsm #ASCO22 @ASCO A nice slide in the talk by @mbeksac56 on clinical presentation of AL amyloidosis👇 https://t.co/djaR…

X post image

6 Jun 2022

RT @hemedoc: #ASCO22 #mmsm Martinez: NK cells have short persistence which limits risk but may also limit long term efficacy. But given low…

X post image

6 Jun 2022

RT @hemedoc: #ASCO22 #mmsm Martinez: NK cell therapies may overcome immune dysfunction in MM patients and reduce immune escape. Low risk of…

X post image

6 Jun 2022

#ASCO22 In the slide below you can see the ongoing trials for patients with smoldering #myeloma
Derman highlights the need for more RCT including an observation control arm #PROs #mmsm

X post image

6 Jun 2022

CONGRESS #ASCO22 | @bdermanmd from @UCCancerCenter timely changing the title of his talk on #SMM from ‘How and when to treat’ to ‘To treat or not to treat’ #mmsm

X post image

6 Jun 2022

RT @jmikhaelmd: A privilege to speak to 9500 people at the ASCO Plenary about myeloma, transplant and disparities. #ASCO22 #whereisdrjoe @I…

X post image

6 Jun 2022

CONGRESS #ASCO22 | Education session Q&A: Sarah Larson, MD @UCLA asked about maximizing benefit while minimizing risks for bispecific antibody therapy

A: Fixed duration therapy, antimicrobial selection and learning how to best use supportive care strategies will be key

#mmsm

X post image

6 Jun 2022

CONGRESS #ASCO22 | @AjayNookaMD @EmoryUniversity presents a fascinating educational session on the role of measurable residual disease (MRD) in #MYELOMA.

#mmsm #cancerawareness #medicalcongress

X post image

5 Jun 2022

X post image

5 Jun 2022

CONGRESS #ASCO22 | Paul Richardson @DanaFarberNews presents the DETERMINATION trial, a massive effort with a median follow-up >6 years #mmsm

X post image

5 Jun 2022

#ASCO22 | Paul Richardson presenting the DETERMINATION trial at the plenary session @DanaFarberNews #mmsm

X post image

5 Jun 2022

CONGRESS #ASCO22 | Madhav V. Dhodapkar @WinshipAtEmory closing the oral abstract session in #myeloma today discussing bispecific antibodies. Great efficacy seen to date and need to better describe infection risk and mitigation strategies #mmsm

X post image

5 Jun 2022

#ASCO22 #mmsm https://t.co/Do1o5YPtil

X post image

5 Jun 2022

#ASCO22 | Further details on elranatamab’s safety profile #mmsm

X post image

5 Jun 2022

CONGRESS #ASCO22 | @LesokhinMD @sloan_kettering presents the initial safety results of elranatamab’s ph II trial (MagnetisMM-3). No Gr3 CRS or ICANS observed; the 2-step-up priming regimen successfully mitigated the rate and severity of CRS #mmsm

X post image

5 Jun 2022

#ASCO22 See below the reasons why these patients would’ve been excluded in the KarMMa trial.
Prior exposure to BCMA-directed therapy was identified as an independent predictor factor of inferior outcomes #mmsm

X post image

5 Jun 2022

CONGRESS #ASCO22 | Ide-cel in real-world patients. Poster presented by Doris Hansen @MoffittNews — Should #CART eligibility be guided by trial criteria? 77% of the patients included in this analysis wouldn’t be eligible for the KarMMa trial #mmsm

X post image

5 Jun 2022

#ASCO22 | Melissa Alsina’s slide summarizing the trials assessing #CART therapy in earlier lines for #myeloma @MoffittNews #mmsm

X post image

5 Jun 2022

To be presented today at the #ASCO22 plenary session! #mmsm https://t.co/dxvhzHVMqH

X post image

5 Jun 2022

RT @ninashah33: Let’s get this party started! 🎉Ready for #myeloma oral abstract session with my co-chair @ravivij #mmsm #ASCO22 Join us i…

X post image

5 Jun 2022

Keep an eye on our Twitter page!
The @MM_Hub will be bringing you comprehensive updates as we continue our live coverage!
🤓Today we will be covering the oral abstract session on plasma cell dyscrasias.
@ASCO #ASCO22 #medicalcongress #cancerawareness #mmsm

X post image

5 Jun 2022

CONGRESS #ASCO22 | Cyrille Touzeau @CHUNantes presents the IFM2018-04 trial. The results of this quad induction therapy for HR patients are in accordance with the GMMG-CONCEPT trial with isa. Longer f-up data will also inform about the results of double ASCT after Dara-KRd #mmsm

X post image

5 Jun 2022

CONGRESS #ASCO22 | Dominik Dytfeld @PUMS_tweets presents the ATLAS trial, which asses the efficacy and safety of MRD-guided KRd maintenance after auto-HSCT #mmsm

X post image

5 Jun 2022

CONGRESS #ASCO22 | Cyrille Touzeau @CHUNantes presents the updated results of the I-Dara trial (without dex), a study designed for elderly frail patients with relapsed #myeloma. The IFM is also evaluating dara+len (no dex) in newly diagnosed patients #mmsm

X post image

4 Jun 2022

Busy day at #ASCO22! Getting ready for the poster discussion session on #myeloma later today #mmsm

X post image

4 Jun 2022

🤩Great slide summarizing the treatment landscape in #myeloma #mmsm #ASCO22

X post image

4 Jun 2022

CONGRESS #ASCO22 | @YiLinMDPhD shares her insights on the use of #CART in #myeloma in the US, highlighting the importance of early referral, the complex patient journey, and the limited experience in special populations #mmsm

X post image

4 Jun 2022

RT @JCO_ASCO: ‼️ #ASCO22 simultaneous publication in #JCO by Thomas Martin, MD et al: Ciltacabtagene Autoleucel, an Anti-B-cell Maturation…

X post image

3 Jun 2022

@ASCO starts today!
The @MM_Hub will be covering ASCO virtually and in person!

Today we will attend: "New Drugs in Oncology: Incorporation into practice"

Keep an eye on our Twitter page for live updates!

#ASCO22 #medicalcongress #cancerawareness #mmsm

X post image

31 May 2022

The @MM_Hub will be covering the 2022 ASCO Annual Meeting!

Date: 3–7 June
Location: Hybrid

Keep an eye on our socials for live coverage throughout the day from our virtual and in-person attendance in Chicago, IL! 🗣💻

#ASCO22 #medicalcongress #cancerawareness

X post image

27 May 2022

NEWS 🚨
Cilta-cel, a BCMA-directed #CARTcell therapy, approved by the @EU_Commission for the treatment of patients with relapsed/refractory #myeloma. Read all the details here 👇
#mmsm #mednews #ASCO22 #EHA2022

https://t.co/L7Wfx5SgV2

<span> </span>

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

More about...

ASCO 2022 American Society of Clinical Oncology

Your opinion matters

Regarding bispecific antibodies for multiple myeloma, which of the following do you consider the biggest hurdle for patients and caregivers?

Newsletter

Subscribe to get the best content delivered to your inbox